Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00949949 · ClinicalTrials.gov registry record · Phase 1

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
38
Enrollment target
3
Study locations

NCT00949949 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00949949, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Unresectable Gallbladder Cancer, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
38 participants
Enrollment target
3
Study locations

Study Summary

This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy. Drugs used in chemotherapy, such as everolimus, gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Unresectable Gallbladder Cancer Cholangiocarcinoma of the Gallbladder Localized Gallbladder Cancer

Interventions

  • DRUG cisplatin
  • DRUG everolimus
  • DRUG gemcitabine hydrochloride

Study Locations (3)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2009-09
Est. Completion 2014-07
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00949949

The ClinicalTrials.gov registry entry for NCT00949949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.

NCT00949949 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00949949 about?

NCT00949949 is a clinical study titled "Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy". This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy. Drugs used in chemotherapy, such as everolimus, gemcitabine hydrochloride, and cisplati...

What is the current status of trial NCT00949949?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2009-09. Estimated completion is 2014-07.

What conditions does trial NCT00949949 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Unresectable Gallbladder Cancer, Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer.

What interventions are being tested in trial NCT00949949?

The interventions under investigation include: cisplatin (DRUG), everolimus (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00949949?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00949949 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Unresectable Gallbladder Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.